Login to Your Account



Gentium's Defibrotide Brings 2Q Sales Record as Launch Looms

By Cormac Sheridan
Staff Writer

Tuesday, August 13, 2013
Buoyed by the European Medicines Agency's recent reversal of its earlier negative decision on Defitelio (defibrotide), Gentium SpA unveiled its best ever quarter for the product and set out its stall on growing the market, albeit within a narrower indication.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription